Search
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalIn July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803] … [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.
Synonyms: 2-chloro-N-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-Oveporexton
go.drugbank.com/drugs/DB21680Approved[L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms. … [L64068] NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other
Rexin G
go.drugbank.com/drugs/DB16450InvestigationalIt is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry. … Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene.
N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine
go.drugbank.com/drugs/DB14196ApprovedSensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test. … N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen.
Synonyms: N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine, N-Cyclohexyl-N'-phenyl-p-phenylendiamineSulfathiazole
go.drugbank.com/drugs/DB06147ApprovedVet approvedWithdrawnSulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamid...
Synonyms: N1-2-Thiazolylsulfanilamide, N(1)-2-ThiazolylsulfanilamideUCB7362
go.drugbank.com/drugs/DB17096Experimental[A254222] Plasmepsins are aspartyl proteases produced by the malaria parasite _Plasmodium falciparum_, and PMX is considered to be essential for parasite egress and invasion. … It has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC<sub>50</sub> = 10 nM), and _in vivo_ (50 mg/kg dose
Corynebacterium diphtheriae
go.drugbank.com/drugs/DB09877ApprovedInvestigational*Corynebacterium diphtheriae* toxin is extracted from the pathogenic actinobacterium *C. diphtheriae* that causes diphtheria.
Isoflurophate
go.drugbank.com/drugs/DB00677ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 29th ed, p1330)
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid